COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04176718
Recruitment Status : Not yet recruiting
First Posted : November 25, 2019
Last Update Posted : November 25, 2019
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Andrew Yee, MD, Dana-Farber Cancer Institute

Brief Summary:

This research study is studying the combination of Carfilzomib and Daratumumab with two standard of care drugs Pomalidomide, and Dexamethasone in people with relapsed and refractory Multiple Myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.

This research study involves two study drugs and two standard of care drugs.

  • The names of the study drugs involved in this study are:

    • Carfilzomib
    • Daratumumab
  • The names of the standard of care drugs involved in this study are:

    • Dexamethasone
    • Pomalidomide

Condition or disease Intervention/treatment Phase
Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma in Relapse Relapse Drug: Daratumumab Drug: Carfilzomib Drug: Pomalidomide Drug: Dexamethasone Phase 2

Detailed Description:

This phase II, multicenter, open-label study is studying Daratumumab in combination with weekly Carfilzomib, Pomalidomide, and Dexamethasone in people with relapsed and refractory Multiple Myeloma who have received at least one prior therapy and who have had previous treatment with both Lenalidomide and a Proteasome inhibitor.

  • The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves two study drugs and two standard of care drugs.
  • The names of the study drugs involved in this study are:

    • Carfilzomib
    • Daratumumab
  • The names of the standard of care drugs involved in this study are:

    • Dexamethasone
    • Pomalidomide
  • A total of 43 participants will be enrolled to this trial
  • The U.S. Food and Drug Administration (FDA) has not approved Daratumumab, and Carfilzomib for use in treatment of Multiple Myeloma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2024

Arm Intervention/treatment
Experimental: Daratumumab,Carfilzomib, Pomalidomide and Dexamethasone

Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.

Participants will receive daratumumab, carfilzomib, pomalidomide, and dexamethasone on a 28 day schedule.

  • Daratumumab will be given according to cycle and dosage determined by protocol.
  • Carfilzomib will be given 3 times per cycle
  • Pomalidomide will be given daily during cycle.
  • Dexamethasone will be given 8 times per cycle.
Drug: Daratumumab
predetermined dose, intravenously, at predetermined times per cycle
Other Name: Darzalex

Drug: Carfilzomib
predetermined dose, intravenously, give 3 times per cycle
Other Name: Kyprolis

Drug: Pomalidomide
predetermined dose, orally, daily per cycle
Other Names:
  • Pomalyst
  • Imnovid

Drug: Dexamethasone
predetermined dose, orally, given 8 times per cycle
Other Names:
  • Dexasone
  • Diodex
  • hexadrol

Primary Outcome Measures :
  1. Objective response rate of the daratumumab, carfilzomib, pomalidomide, and dexamethasone combination [ Time Frame: 28 Days ]
    Simon's two-stage design will be used. An objective response rate of 40%

  2. Number of dose limiting toxicity grade 4 or higher treatment related [ Time Frame: 28 Days ]

Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: time from randomization to the disease progression or death from any cause up 60 months ]
    PFS will be estimated using the Kaplan-Meier method

  2. Rate of Minimal residual disease (MRD) negative status [ Time Frame: 112 Days ]
    Clonal evolution and clonal heterogeneity will be summarized using descriptive statistics

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women ≥ 18 and ≤ 80 years old
  • Diagnosis of multiple myeloma:

    • Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
    • ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
    • Serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free kappa to serum free kappa light chain ratio
  • Previously treated relapsed and refractory multiple myeloma

    • Patients must have received at least one prior line of therapy;
    • Prior therapy must include at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen)
    • Disease progression on or within 60 days of completion of last therapy.
  • ANC ≥ 1000/μL.

    • G-CSF is not permitted within 14 days of screening.
    • Patients with ANC <1000/µL can be considered for screening on a case by case basis with additional monitoring, after discussion with and approval from the PI.
  • Platelet count ≥ 50,000/µL. Platelet transfusion is not permitted within 7 days of screening.
  • Hemoglobin ≥ 8 g/dL. Red blood cell transfusions are permitted to meet eligibility criteria.
  • Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation.
  • Patient has adequate hepatic function, as evidenced by each of the following:

    • Serum bilirubin values < 2 mg/dL; and
    • Serum aspartate transaminase (ALT) and/or aspartate transaminase (AST) values < 2.5 × the upper limit of normal (ULN) of the institutional laboratory reference range. Patients with elevated bilirubin due to Gilbert's syndrome may be permitted with PI approval (e.g. total bilirubin <3 mg/dL and normal direct bilirubin).
  • Must be able to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin, apixaban, rivaroxaban, or equivalent.
  • All study participants must be registered into the mandatory Pomalyst REMS program and be willing and able to comply with the requirements of the Pomalyst REMS program.
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Pomalyst REMS program.
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g. either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug.
  • Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken).

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study registration or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Patients may have received dexamethasone within 2 weeks prior to study registration.
  • Participants who are receiving any other investigational agents.
  • Last line of therapy with the combination of carfilzomib, pomalidomide, and dexamethasone. Note, prior treatment with daratumumab or other anti-CD38 therapy is permitted. Prior treatment with carfilzomib or pomalidomide is permitted (as different lines of treatment but not in the same combination).
  • Concomitant high dose corticosteroids. Low dose corticosteroids (maximum dose 10 mg/day prednisone equivalent) is permitted if given for disorders other than myeloma, e.g. adrenal insufficiency, rheumatoid arthritis, etc.
  • Pregnancy or lactation or planned lactation (breastfeeding).
  • Prior history of malignancies, other than MM, unless the patient has completed definitive treatment and has been free of the disease for ≥ 3 years. Patients who are free of disease < 3 years may enroll after discussion with and approval of the PI. Exceptions include the following (i.e. the following are eligible to participate):

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Ductal carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b) managed with surveillance
  • Patients with plasma cell leukemia, POEMS syndrome, or amyloidosis are excluded from this trial.
  • Seropositive for HIV infection
  • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]; see exception below). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. Exception: subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
  • Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).
  • Peripheral neuropathy ≥ grade 2 despite supportive therapy.
  • Hypersensitivity to daratumumab, thalidomide, lenalidomide, pomalidomide, carfilzomib, or dexamethasone (such as Stevens-Johnson syndrome). Rash to immunomodulatory drug that can be medically managed is allowable.
  • Allogeneic stem cell transplant <12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least four weeks prior to initiation of study treatment and who are currently dependent on such treatment. Patients may also not have active graft v. host disease (GVHD).
  • Patient has a history of significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory, or inflammatory illness that could preclude study participation, pose an undue medical hazard, or interfere with the interpretation of the study results, including, but not limited to, patients with congestive heart failure (New York Heart Association [NYHA] Class 3 or 4); unstable angina; cardiac arrhythmia; recent (within the preceding 6 months) myocardial infarction or stroke; hypertension requiring > 2 medications for adequate control; diabetes mellitus with > 2 episodes of ketoacidosis in the preceding 12 months; or chronic obstructive pulmonary disease (COPD) requiring > 2 hospitalizations in the preceding 12 months.
  • Known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume [FEV] in 1 second <60% of predicted normal), known moderate or severe persistent asthma within 2 years prior to study registration (intermittent asthma is allowed). Patient with known or suspected COPD or asthma must have an FEV1 test within 28 days prior to study registration.
  • Major surgery within 2 weeks prior to C1D1.
  • Patient has any other medical, psychiatric, or social condition that would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results.
  • Toxicity from previous anticancer therapy must resolve to baseline levels or to grade ≤1, except for alopecia and peripheral neuropathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04176718

Layout table for location contacts
Contact: Andrew J Yee, MD 617-726-2000

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Contact: Andrew J Yee, MD    617-726-2000   
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02155
Contact: Omar Nadeem, MD    617-632-4852   
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Contact: Jacalyn Rosenblatt, MD    617-667-9920   
Principal Investigator: Jacalyn Rosenblatt, MD         
Sponsors and Collaborators
Andrew Yee, MD
Janssen Research & Development, LLC
Layout table for investigator information
Principal Investigator: Andrew J Yee, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Andrew Yee, MD, Sponsor-Investigator, Dana-Farber Cancer Institute Identifier: NCT04176718    
Other Study ID Numbers: 19-379
First Posted: November 25, 2019    Key Record Dates
Last Update Posted: November 25, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: - MGH - Contact the Partners Innovations team at

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Andrew Yee, MD, Dana-Farber Cancer Institute:
Multiple Myeloma
Refractory Multiple Myeloma
Multiple Myeloma in Relapse
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal